Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

J. Nossent, E. Kiss, B. Rozman, G. Pokorny, P. Vlachoyiannopoulos, M. Olesinska, A. Marchesoni, M. Mosca, S. Påi, K. Manger, M. Schneider, H. Nielsen, R. Van Vollenhoven, T. Swaak

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

An inception cohort of patients with systemic lupus erythematosus from 14 European centres was followed for up to 5 years in order to describe the current early disease course. At inclusion patients (n = 200, 89% female, mean age 35 years, 97% Caucasian, mean SLEDAI 12.2) fulfilled a mean of 6.5 ACR classification criteria. The most prevalent criteria were antinuclear Ab presence (97%) followed by anti-dsDNA Ab (74%), arthritis (69%), leukocytopenia (54%) and malar rash (53%), antiphospholipid Ab (48%) and anti-synovial membrane Ab (21.6%). Clinical signs of lupus nephritis (LN) were present in 39% with biopsy-confirmed LN seen in 25%. Frequent additional findings were hypocomplementaemia (54%), anti-SSA Ab (49%), alopecia (26%) and Raynaud's phenomenon (31%). There were few regional differences in disease presentation and management. One and 5-year survival rates were 99% and 97% respectively. During the mean follow-up of 4.1 years 25% entered a state of early disease quiescence by global physician assessment, but the overall risk of subsequent flare was 60%. Maximum SLEDAI scores decreased over time, but 45% of patients accrued damage (SDI ≥1) for which baseline presence of proteinuria and persistent disease activity were independent predictors. The results indicate minor differences in SLE presentation and treatment within various regions of Europe and a high diagnostic reliance on anti-dsDNA Ab. Despite early reductions in disease activity and improved mortality, the risk for disease flare and damage development is, however, still substantial, especially in patients not entering an early remission.

Original languageEnglish
Pages (from-to)949-956
Number of pages8
JournalLupus
Volume19
Issue number8
DOIs
Publication statusPublished - 2010

Fingerprint

Systemic Lupus Erythematosus
Lupus Nephritis
Raynaud Disease
Synovial Membrane
Alopecia
Leukopenia
Disease Management
Exanthema
Proteinuria
Arthritis
Survival Rate
Physicians
Biopsy
Mortality
Therapeutics

Keywords

  • damage accrual
  • disease activity
  • Europe
  • inception cohort
  • systemic lupus erythematosus
  • therapy

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. / Nossent, J.; Kiss, E.; Rozman, B.; Pokorny, G.; Vlachoyiannopoulos, P.; Olesinska, M.; Marchesoni, A.; Mosca, M.; Påi, S.; Manger, K.; Schneider, M.; Nielsen, H.; Van Vollenhoven, R.; Swaak, T.

In: Lupus, Vol. 19, No. 8, 2010, p. 949-956.

Research output: Contribution to journalArticle

Nossent, J, Kiss, E, Rozman, B, Pokorny, G, Vlachoyiannopoulos, P, Olesinska, M, Marchesoni, A, Mosca, M, Påi, S, Manger, K, Schneider, M, Nielsen, H, Van Vollenhoven, R & Swaak, T 2010, 'Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus', Lupus, vol. 19, no. 8, pp. 949-956. https://doi.org/10.1177/0961203310366572
Nossent, J. ; Kiss, E. ; Rozman, B. ; Pokorny, G. ; Vlachoyiannopoulos, P. ; Olesinska, M. ; Marchesoni, A. ; Mosca, M. ; Påi, S. ; Manger, K. ; Schneider, M. ; Nielsen, H. ; Van Vollenhoven, R. ; Swaak, T. / Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. In: Lupus. 2010 ; Vol. 19, No. 8. pp. 949-956.
@article{d781615ceafc4d3eadb1d65d2af342c0,
title = "Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus",
abstract = "An inception cohort of patients with systemic lupus erythematosus from 14 European centres was followed for up to 5 years in order to describe the current early disease course. At inclusion patients (n = 200, 89{\%} female, mean age 35 years, 97{\%} Caucasian, mean SLEDAI 12.2) fulfilled a mean of 6.5 ACR classification criteria. The most prevalent criteria were antinuclear Ab presence (97{\%}) followed by anti-dsDNA Ab (74{\%}), arthritis (69{\%}), leukocytopenia (54{\%}) and malar rash (53{\%}), antiphospholipid Ab (48{\%}) and anti-synovial membrane Ab (21.6{\%}). Clinical signs of lupus nephritis (LN) were present in 39{\%} with biopsy-confirmed LN seen in 25{\%}. Frequent additional findings were hypocomplementaemia (54{\%}), anti-SSA Ab (49{\%}), alopecia (26{\%}) and Raynaud's phenomenon (31{\%}). There were few regional differences in disease presentation and management. One and 5-year survival rates were 99{\%} and 97{\%} respectively. During the mean follow-up of 4.1 years 25{\%} entered a state of early disease quiescence by global physician assessment, but the overall risk of subsequent flare was 60{\%}. Maximum SLEDAI scores decreased over time, but 45{\%} of patients accrued damage (SDI ≥1) for which baseline presence of proteinuria and persistent disease activity were independent predictors. The results indicate minor differences in SLE presentation and treatment within various regions of Europe and a high diagnostic reliance on anti-dsDNA Ab. Despite early reductions in disease activity and improved mortality, the risk for disease flare and damage development is, however, still substantial, especially in patients not entering an early remission.",
keywords = "damage accrual, disease activity, Europe, inception cohort, systemic lupus erythematosus, therapy",
author = "J. Nossent and E. Kiss and B. Rozman and G. Pokorny and P. Vlachoyiannopoulos and M. Olesinska and A. Marchesoni and M. Mosca and S. P{\aa}i and K. Manger and M. Schneider and H. Nielsen and {Van Vollenhoven}, R. and T. Swaak",
year = "2010",
doi = "10.1177/0961203310366572",
language = "English",
volume = "19",
pages = "949--956",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

AU - Nossent, J.

AU - Kiss, E.

AU - Rozman, B.

AU - Pokorny, G.

AU - Vlachoyiannopoulos, P.

AU - Olesinska, M.

AU - Marchesoni, A.

AU - Mosca, M.

AU - Påi, S.

AU - Manger, K.

AU - Schneider, M.

AU - Nielsen, H.

AU - Van Vollenhoven, R.

AU - Swaak, T.

PY - 2010

Y1 - 2010

N2 - An inception cohort of patients with systemic lupus erythematosus from 14 European centres was followed for up to 5 years in order to describe the current early disease course. At inclusion patients (n = 200, 89% female, mean age 35 years, 97% Caucasian, mean SLEDAI 12.2) fulfilled a mean of 6.5 ACR classification criteria. The most prevalent criteria were antinuclear Ab presence (97%) followed by anti-dsDNA Ab (74%), arthritis (69%), leukocytopenia (54%) and malar rash (53%), antiphospholipid Ab (48%) and anti-synovial membrane Ab (21.6%). Clinical signs of lupus nephritis (LN) were present in 39% with biopsy-confirmed LN seen in 25%. Frequent additional findings were hypocomplementaemia (54%), anti-SSA Ab (49%), alopecia (26%) and Raynaud's phenomenon (31%). There were few regional differences in disease presentation and management. One and 5-year survival rates were 99% and 97% respectively. During the mean follow-up of 4.1 years 25% entered a state of early disease quiescence by global physician assessment, but the overall risk of subsequent flare was 60%. Maximum SLEDAI scores decreased over time, but 45% of patients accrued damage (SDI ≥1) for which baseline presence of proteinuria and persistent disease activity were independent predictors. The results indicate minor differences in SLE presentation and treatment within various regions of Europe and a high diagnostic reliance on anti-dsDNA Ab. Despite early reductions in disease activity and improved mortality, the risk for disease flare and damage development is, however, still substantial, especially in patients not entering an early remission.

AB - An inception cohort of patients with systemic lupus erythematosus from 14 European centres was followed for up to 5 years in order to describe the current early disease course. At inclusion patients (n = 200, 89% female, mean age 35 years, 97% Caucasian, mean SLEDAI 12.2) fulfilled a mean of 6.5 ACR classification criteria. The most prevalent criteria were antinuclear Ab presence (97%) followed by anti-dsDNA Ab (74%), arthritis (69%), leukocytopenia (54%) and malar rash (53%), antiphospholipid Ab (48%) and anti-synovial membrane Ab (21.6%). Clinical signs of lupus nephritis (LN) were present in 39% with biopsy-confirmed LN seen in 25%. Frequent additional findings were hypocomplementaemia (54%), anti-SSA Ab (49%), alopecia (26%) and Raynaud's phenomenon (31%). There were few regional differences in disease presentation and management. One and 5-year survival rates were 99% and 97% respectively. During the mean follow-up of 4.1 years 25% entered a state of early disease quiescence by global physician assessment, but the overall risk of subsequent flare was 60%. Maximum SLEDAI scores decreased over time, but 45% of patients accrued damage (SDI ≥1) for which baseline presence of proteinuria and persistent disease activity were independent predictors. The results indicate minor differences in SLE presentation and treatment within various regions of Europe and a high diagnostic reliance on anti-dsDNA Ab. Despite early reductions in disease activity and improved mortality, the risk for disease flare and damage development is, however, still substantial, especially in patients not entering an early remission.

KW - damage accrual

KW - disease activity

KW - Europe

KW - inception cohort

KW - systemic lupus erythematosus

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=77954074375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954074375&partnerID=8YFLogxK

U2 - 10.1177/0961203310366572

DO - 10.1177/0961203310366572

M3 - Article

C2 - 20375124

AN - SCOPUS:77954074375

VL - 19

SP - 949

EP - 956

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 8

ER -